Tocilizumab and steroid treatment in patients with COVID-19 pneumonia
코로나19 폐렴 환자에서 토실리주맙과 스테로이드 치료
Research Article
[키워드] 95%CI
adjusted
age
analyses
anti-inflammatory treatment
Comorbidities
Comorbidity
controls
coronavirus disease
Coronavirus disease 2019
COVID-19
COVID-19 pneumonia
Cox regression analysis
darunavir
death
defined
determine
difference
early treatment
Efficacy
Endpoint
endpoints
Evidence
failure
group
hazard
hazard ratio
Hospital admission
Hydroxychloroquine
immune response
IMPROVE
intravenously
Intubated
intubation
IQR
lead
male
median
median age
Methylprednisolone
non-intubated patient
non-intubated patients
not intubated
outcome
overall survival
PaO
Patient
patients with COVID-19
Pneumonia
primary endpoint
Propensity score
Ratio
Respiratory failure
Result
Ritonavir
Severe COVID-19 pneumonia
single-center study
Standard of care
steroid
steroid treatment
Steroids
subcutaneously
survival
Tocilizumab
treated patient
Treatment
treatment with tocilizumab
with COVID-19
[DOI] 10.1371/journal.pone.0237831 PMC 바로가기 [Article Type] Research Article
[DOI] 10.1371/journal.pone.0237831 PMC 바로가기 [Article Type] Research Article